Aranesp®

DRUG9 trials

Sponsors

Amgen, Biocad

Conditions

AnemiaCancerChronic Renal FailureEnd Stage Renal DiseaseKidney DiseaseNeoplasmsReticulocyte Count

Phase 1

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

CompletedNCT02731469

BiocadReticulocyte Count

Start: 2016-06-15End: 2017-03-31Updated: 2019-07-01

Phase 2

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

CompletedNCT00144131

AmgenAnemia, Cancer

Start: 2005-08-31Target: 750Updated: 2013-05-24

Phase 3

Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis

CompletedNCT00116701

AmgenKidney Disease

Start: 2005-05-31Target: 200Updated: 2008-05-05

Phase 4

Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

CompletedNCT00111995

AmgenAnemia, Chronic Renal Failure

Start: 2002-05-31Target: 400Updated: 2008-08-08

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

CompletedNCT00117065

Updated: 2013-04-26

Aranesp® Monthly Preference Study - 2

CompletedNCT00117078

AmgenKidney Disease

Updated: 2008-09-30

A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

CompletedNCT00117039

AmgenAnemia, Neoplasms

Start: 2004-01-31End: 2005-04-30Target: 1500Updated: 2008-10-15

Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis

CompletedNCT00117104

AmgenEnd Stage Renal Disease

Updated: 2009-10-16

Study to Evaluate Effectiveness of Aranesp®

CompletedNCT00117130

AmgenKidney Disease

Updated: 2011-01-21

Related Papers

Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.

2010-10-255 citations